Blurred lines? All about macular degeneration

Written by: Mr Allaaeldin Abumattar
Published: | Updated: 14/06/2022
Edited by: Karolyn Judge

Macular degeneration (AMD), also known as age-related macular degeneration, can lead to blurriness or no vision in the central field of vision. Despite AMD being a natural occurrence, there are ways to slow down and even reverse any vision loss that people may have.


Here to offer a detailed insight to the condition, particularly when it comes to delaying AMD is highly experienced consultant ophthalmic surgeon Mr Allaaeldin Abumattar.


Stylish older woman with AMD sat on the floor


What is macular degeneration?

Age-related macular degeneration (AMD) is a condition that naturally occurs with ageing. It tends to result in gradual deterioration of central vision due to the irreversible wear and tear of sensitive cells at the back of the eye (photoreceptors), characterised by slow deterioration of central vision, which may - in some cases - lead to irreversible central vision loss. The central vision is the most used part of our eyes. It picks out fine details, colours and shapes of objects to create a crisp, clear picture. It allows us to read, drive, dial the telephone, recognise faces and see objects; to perform our daily tasks and routines.



What is the main cause of macular degeneration?

Causes of AMD are not fully understood, but increasing age, genes, weight, diet, and some lifestyle factors are known to increase the chances of developing it.


The sensitive cells at the back of the eye (photoreceptors) sit atop a layer of cells called retinal pigment epithelial cells (RPE). The RPE layer does a very important job in our eyes. It transports oxygen and essential nutrients to photoreceptors and recycles their waste products. As we age, the RPE layer loses its effective recycling leading to the accumulation of ‘waste’ in the RPE layer called drusen. Drusen, genetic and environmental factors ultimately damage our aging photoreceptors.



Who is most at risk of macular degeneration?

A person’s risk of developing AMD increases with age. In the UK, AMD affects over 600,000 people where about one in 20 people aged over 65, and about one in eight people aged over 80 have AMD severe enough to cause serious visual loss.


Having a first-degree relative diagnosed with AMD increases the relative risk of developing it. It’s important here to emphasise that it’s not only genetic factors that play a role in AMD development.  Drusen (sensitive cells waste), genetic and environmental factors all contribute. Genetics alone are not definitive for the occurrence or progression of the disease. Patients that have genotypes that are known to be high-risk may not develop AMD.



Can macular degeneration be prevented? If so, how?

The good news is that our knowledge and recent advances in AMD treatment are helping to slow down and prevent further worsening - and sometimes reverse - the vision loss caused by AMD. Ways to prevent or slow the disease are:


  • Stopping smoking

It’s been consistently shown in research how smoking increases the risk of developing AMD. It’s been found that current smokers are up to four times more likely to have AMD in comparison to people who’ve never smoked.


Smokers are more likely to develop AMD up to 10 years earlier in comparison to those who have never smoked.


AMD in smokers is likely to progress faster and be less responsive to treatment.


The risk of AMD is also likely to increase if a person is around second-hand smoke.  


Stop smoking services can help you to quit. You’re up to four-times more likely to quit successfully with the help of these services.



  • Dietary supplements vs Age Related Eye Disease Study 2® (AREDS2®)

The damage that oxidant substances can cause, can be negated by certain nutrients that protect the body. Antioxidants reduce the harmful effect of oxidants. Examples of antioxidants are vitamins A, C and E.  Lutein and zeaxanthin are pigments on our eyes that act as a natural sunblock to protect our central vision. Our body cannot make them. They must be consumed in food. Several studies suggest that at least 10mg of lutein a day has the most beneficial effect on our central vision, and diet alone cannot provide the sufficient levels of vitamins and minerals required for AMD risk reduction. The average western diet contains no more than 3mg of lutein and zeaxanthin a day.


Kale is the best source of lutein, even when raw. Lutein and zeaxanthin are found in eggs, and they may be absorbed more easily by the body because they’re eaten with the fat that’s contained in the egg. Orange and yellow fruits and vegetables such as sweetcorn and orange peppers contain zeaxanthin, and many of them also contain vitamins C and E


Milligrams (mg) of lutein per 100g fresh vegetables: 11.4 mg in kale, 8.5 mg in red pepper, 7.9 mg in spinach, 4.7 mg in lettuce, 3.6 mg in leek, 3.3 mg in broccoli, 1.7 mg in peas.


AREDS2® dietary supplements will not prevent or cure AMD. They may just delay the progression of AMD to help you keep your vision longer. AREDS2®can lower the risk of getting late AMD in the other eye.


AREDS2® can reduce your risk of developing advanced AMD by about 25 per cent after 5 years of using the formula.


Table illustrating AREDS2 tm formula for AMD treatment


  • Know your family history

Those who have a first-degree relative that is, or has been, affected by AMD, have a significant risk of developing it.  These people should look out potential symptoms, which include difficulty recognising faces, struggling to adapt to low light and seeing straight lines that appear wavy.  



If macular degeneration is treated, can it reoccur?

AMD has no cure yet. However; treatment options available can control the disease successfully in most of patients. It is essential to keep regular follow ups. Studies show that, on average, patients need between six to eight eye injections a year to control wet macular degeneration recurrence. Some patients may need fewer, some patients more, but long-term, sustained AMD treatment is important to treat recurrence of the disease.


Since wet AMD involves scarring that cannot be reversed, early detection of wet AMD is critical. Patients typically have more satisfactory results with anti-VEGF treatment when AMD is caught early, before significant scarring has occurred. One third of treated patients might get some of their lost vision back after treatment. Nine out of 10 patients have a chance of treatment being successful in preventing central vision loss from worsening.


Most people with macular degeneration have the more common form, dry AMD, in one or both eyes. In one out of 10 people, dry AMD progresses to wet AMD.



If you’re looking for expert treatment for AMD or other ophthalmic issues, arrange an appointment with Mr Abumattar via his Top Doctors profile.

By Mr Allaaeldin Abumattar

Mr Allaaeldin Abumattar is an exceptionally well-regarded and highly experienced consultant ophthalmic surgeon who specialises in cataract surgeryage-related macular degeneration (AMD)diabetic retinopathy, retinal vein occlusions as well as glaucoma.  Mr Abumattar moved to Swindon in January 2017, where he is currently the age-related macular degeneration (AMD) clinical lead, and is the ophthalmology clinical tutor for university medical school students. 

Mr Abumattar possesses an extensive amount of experience in relation to the management of eyelid conditions and disorders, such as lower lid and upper lid malposition surgerytherapeutic botulinum toxin injection as an effective treatment option for facial dystonia and thyroid eye disease. Impressively, Mr Abumattar developed and provided a structured approach to both the data collection and decision-making in relation to the overall management of thyroid eye disease, which, in 2014, was presented to The British Oculoplastic Surgery Society. 

Following his graduation in 1994; obtaining a degree in medicine from the established Al Fetah University; Mr Abumattar undertook his training in ophthalmology at both the El Nasir Ophthalmic Hospital and the St John of Jerusalem Eye Hospital. He then moved to the UK in 2001, immediately undertaking training posts at the Ayrshire and Arran Acute Hospitals Trust. Following this, he began at a post at the Stoke Mandeville Hospital, where he was awarded with the SAS (Staff grade and Associate Specialists) Clinical Discretionary Award in 2006. 

Throughout his career, Mr Abumattar has developed quite the interest in the incorporation of standard and premium implant for cataract surgery and also for effectively correcting astigmatism. He has taught and trained many in the area of ophthalmology to-date, and has engaged himself in clinical trials. He also won the Best Presentation Prize in the SAS Regional Academic Study Day, 2013, for his tips on delivering virtually painless ocular injections in the management of age-related macular degeneration study on "Pain Scores Following Intravitreal Injections." In addition, Mr Abumattar most notably held an honorary fellowship post at Moorfields Eye Hospital in 2013. 

Moreover, Mr Abumattar achieved responsibilities as Trust Appraiser, the Director of the Buckinghamshire Postgraduate Ophthalmology Teaching Programme, Member of the Joint Consultation and Negotiating Committee (JCNC) for doctors and dentists in Oxfordshire Deanery, representative in the Royal College of Ophthalmologists SAS group, and SAS representative in Royal College revalidation sub-committee. He was also awarded a Local Clinical Excellence Award in 2021 in recognition for his service to the NHS. 

View Profile

Overall assessment of their patients

This website uses our own and third-party Cookies to compile information with the aim of improving our services, to show you advertising related to your preferences as well analysing your browsing habits. You can change your settings HERE.